2024-09-18 - Analysis Report
## Stock Analysis Report for ABBV (AbbVie Inc.)

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company developing and marketing therapies for a range of diseases including immunology, oncology, virology, neurology, eye care, and women's health.

**Performance Analysis:**

**1. Return Comparison:**

* ABBV's cumulative return is 102.08%, compared to 88.56% for the S&P 500 (VOO). 
* This shows ABBV has outperformed the market with a 13.52% difference in cumulative return. 
* The relative divergence is 61.92%, indicating that ABBV's current performance is above the 61.92 percentile of its historical performance against the S&P 500.

**2. Recent Price Movements:**

* **Closing Price:** 192.75
* **5-day Moving Average:** 194.26
* **20-day Moving Average:** 195.74
* **60-day Moving Average:** 184.27

This suggests a slight downward trend in recent price action as the current price sits below the 5-day and 20-day moving averages. The 60-day moving average is below the current price, indicating potential upward momentum.

**3. Technical Indicators:**

* **RSI:** 43.55 - This indicates that the stock is currently in the neutral territory, not overly overbought or oversold.
* **PPO:** -0.5 - A negative PPO value suggests that the stock is currently experiencing a short-term downtrend.
* **Delta_Previous_Relative_Divergence:** -5.73 - This indicates a recent short-term downward trend in relative divergence, suggesting a potential slowdown in ABBV's performance compared to the S&P 500.
* **Expected Return:** 18.02% - This is the estimated maximum return over the next 5 years based on current investment amount.

**4. Recent Earnings & Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

ABBV has consistently exceeded earnings expectations in recent quarters. The most recent earnings report for Q2 2024 shows an EPS of 2.65, exceeding the estimated EPS of 2.57, suggesting a positive outlook for the company's earnings potential.

**Overall Analysis:**

ABBV's recent performance has been positive, exceeding both its historical performance and the market's overall performance. The stock's price action suggests a potential slowdown in its recent momentum, but technical indicators suggest a neutral to slightly bullish outlook. The company's strong earnings track record and continued exceeding of expectations point towards a promising future for ABBV.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as investment advice. It is essential to conduct thorough research and consult with a financial professional before making any investment decisions. 
